|Status: One Wales interim decision|
Using the agreed starting and stopping criteria, ustekinumab (Stelara®▼) can be made available within NHS Wales for the treatment of inflammatory bowel disease in children and young people aged 6 to 17 years: for ulcerative colitis following loss of response, non-response or intolerance to anti-TNF therapies and vedolizumab; for Crohn’s disease following loss of response, non-response or intolerance to anti-TNF therapies.
The risks and benefits of the off-label use of ustekinumab (Stelara®▼) for this indication should be clearly stated and discussed with the patient to allow informed consent.
Providers should consult the relevant guidelines on prescribing unlicensed medicines before any off-label medicines are prescribed.
This advice will be reviewed after 12 months or earlier if new evidence becomes available.
|Medicine name||ustekinumab (Stelara®)|
Treatment of inflammatory bowel disease in children and young people aged 6 to 17 years
|BNF chapter||Gastro-intestinal system|
|Submission type||One Wales|
|Status||One Wales interim decision|
|Date of issue||02/03/2023|